151 related articles for article (PubMed ID: 35980130)
1. SCLC's Treatment Arsenal Improving.
Cancer Discov; 2022 Oct; 12(10):OF1. PubMed ID: 35980130
[TBL] [Abstract][Full Text] [Related]
2. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
[TBL] [Abstract][Full Text] [Related]
3. Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer.
Sanborn RE; Schneiders FL; Senan S; Gadgeel SM
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-14. PubMed ID: 35671433
[TBL] [Abstract][Full Text] [Related]
4. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
5. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
7. The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
Friedlaender A; Liu SV; Passaro A; Metro G; Banna G; Addeo A
Clin Lung Cancer; 2020 Nov; 21(6):e539-e543. PubMed ID: 32499210
[TBL] [Abstract][Full Text] [Related]
8. [Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs].
Song Y; Tang L; Xia L; Tong X; Yang Z
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):684-688. PubMed ID: 36172734
[TBL] [Abstract][Full Text] [Related]
9. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Progress in the Immunotherapy of Small Cell Lung Cancer].
Wang W; Zhang J; Li S
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):425-433. PubMed ID: 35747922
[TBL] [Abstract][Full Text] [Related]
12. [Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors
of Small Cell Lung Cancer].
Yang Y; Wang Y
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):897-903. PubMed ID: 32773012
[TBL] [Abstract][Full Text] [Related]
13. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Small Cell Lung Cancer: Is It Also a Matter of Helios- Cells?
Mormile R
Pathol Oncol Res; 2020 Apr; 26(2):1355-1356. PubMed ID: 30927205
[No Abstract] [Full Text] [Related]
15. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis.
Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
Int Immunopharmacol; 2021 Jul; 96():107594. PubMed ID: 33798808
[TBL] [Abstract][Full Text] [Related]
16. New Immunotherapy and Lung Cancer.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
[TBL] [Abstract][Full Text] [Related]
17. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
18. A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer.
Gill J; Cetnar JP; Prasad V
Trends Cancer; 2020 Sep; 6(9):736-738. PubMed ID: 32616400
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab.
Koulouris A; Mountzios G
Expert Rev Clin Pharmacol; 2021 Jun; 14(6):651-659. PubMed ID: 33902379
[TBL] [Abstract][Full Text] [Related]
20. IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer.
Huang C; Gan GN; Zhang J
J Hematol Oncol; 2020 Jun; 13(1):69. PubMed ID: 32503595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
